Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + risedronate sodium + chemotherapy
- Development stage
- Unknown
- Lead developer
- Harbin Medical University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This investigational combination therapy, being studied by Harbin Medical University, is a triple-regimen treatment for triple-negative breast cancer (TNBC). It consists of camrelizumab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor to restore T-cell mediated anti-tumor immune responses; risedronate sodium, a bisphosphonate that inhibits farnesyl pyrophosphate synthase (FDPS) within the mevalonate pathway to remodel the tumor immune microenvironment and exert direct anti-proliferative effects; and a chemotherapy backbone (such as TAC or AC-T). The combination is designed to synergistically enhance objective response rates and overcome immune resistance in patients with TNBC by combining immune checkpoint blockade with metabolic modulation.
- Other names
- Camrelizumab Plus Risedronate and Chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)FDPS (Farnesyl pyrophosphate synthase)
Beyond the preview
Go deeper on camrelizumab + risedronate sodium + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + risedronate sodium + chemotherapy.